Abbott Labs will present clinical trial results from two different interferon-free, Phase II studies for the treatment of Hepatitis C...
Eisai and Biogen Inc announced that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD(TM)) March 15-20 in Barcelona, Spain and virtually.